{
    "medicine_id": "42314dd878fb379538d77517397601bde502f47e",
    "platform_id": "DB13931",
    "metadata": {
        "name": "Rhokiinsa 200 MCG ML Solution drops",
        "composition": "200 MCG ML Netarsudil",
        "clinical_particulars": {
            "therapeutic_indications": "Netarsudil is indicated for the reduction of elevated intraocular pressure IOP in patients with open angle glaucoma or ocular hypertension FDA Label",
            "contraindications": {
                "disease": "The most common adverse reaction associated with netarsudil dosed once daily in controlled clinical studies was conjunctival hyperemia which was reported by 53 of patients Other common adverse affects reported about 20 include corneal verticillata instillation site pain and even conjunctival hemorrhage Still other reactions include instillation site erythema corneal staining blurred vision increased lacrimiation erythema of eyelid and reduced visual acuity being reported by 5 10 of patients in clinical studies FDA Label When using multiple dose containers of topical ophthalmic products there is a possibilty of contaminating the containers with agents that may cause bacterial keratitis by patients who in many cases have a concurrent corneal disease or a disruption of the ocular epithelial surface FDA Label Although systemic exposure to netarsudil from ocular administration is low there is no formal available data on the safe use of netarsudil in pregnant women FDA Label There is no formal data available on whether significant netarsudil levels could be present in human milk following ocular administration on the effects on the breastfed enfant or on the effects on milk production FDA Label The safety and effectiveness of using netarsudil in pediatric patients below the age of 18 years have not been established FDA Label No overall differences in safety or effectiveness have been observed between elderly and other aduly patients FDA Label Long term studies in animals have not been performed to evaluate the carcinogenic potential of netarsudil Netarsudil was not mutagenic in the Ames test in the mouse lymphoma test or in the in vivo rat micronucleus test Studies to evaluate the effects of netarsudil on male or female fertility in animals have not been performed FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Aqueous humour flows out of the eye via two pathways 1 the conventional trabecular pathway and 2 the unconventional uveoscleral pathway And although it has been shown that the conventional trabecular pathway accounts for most aqueous outflow due to various pathologies most medications available for treating glaucoma target the uveoscleral pathway for treatment and leave the diseased trabecular pathway untreated and unhindered in its progressive deterioration and dysfunction A31476 Netarsudil is subsequently a novel glaucoma medication that is both a rho kinase and norepinephrine transport NATs s inhibitor that specifically targets and inhibits rho kinase and NATS found in the conventional trabecular pathway while many of its contemporaries offer therapy that focuses on cell and muscle tissue remodelling A31476 A31285",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}